Dabigatran etexilate and Gingival bleeding - a phase IV clinical study of FDA data
Gingival bleeding is reported only by a few people who take Dabigatran Etexilate.
The phase IV clinical study analyzes which people take Dabigatran etexilate and have Gingival bleeding. It is created by eHealthMe based on reports of 695 people who have side effects while taking Dabigatran etexilate from the FDA, and is updated regularly.
Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.
695 people reported to have side effects when taking Dabigatran etexilate.
Among them, 2 people (0.29%) have Gingival bleeding.
What is Dabigatran etexilate?
Dabigatran etexilate has active ingredients of dabigatran etexilate. eHealthMe is studying from 584 Dabigatran etexilate users for its effectiveness, alternative drugs and more.
What is Gingival bleeding?
Gingival bleeding (bleeding gums) is found to be associated with 1,578 drugs and 976 conditions by eHealthMe.
Number of Dabigatran etexilate and Gingival bleeding reports submitted per year:
Time on Dabigatran etexilate when people have Gingival bleeding *:
- < 1 month: 0.0 %
- 1 - 6 months: 0.0 %
- 6 - 12 months: 0.0 %
- 1 - 2 years: 100 %
- 2 - 5 years: 0.0 %
- 5 - 10 years: 0.0 %
- 10+ years: 0.0 %
Gender of people who have Gingival bleeding when taking Dabigatran etexilate *:
- female: 50 %
- male: 50 %
Age of people who have Gingival bleeding when taking Dabigatran etexilate *:
- 0-1: 0.0 %
- 2-9: 0.0 %
- 10-19: 0.0 %
- 20-29: 0.0 %
- 30-39: 0.0 %
- 40-49: 0.0 %
- 50-59: 50 %
- 60+: 50 %
Common drugs people take besides Dabigatran etexilate *:
- Pradaxa: 1 person, 50.00%
Common side effects people have besides Gingival bleeding *:
- Thrombocytopenia (decrease of platelets in blood): 1 person, 50.00%
- Swelling Face: 1 person, 50.00%
- Haemorrhage Subcutaneous (bleeding from skin): 1 person, 50.00%
Common conditions people have *:
- Urinary Tract Infection: 1 person, 50.00%
- Platelet Aggregation Inhibition: 1 person, 50.00%
* Approximation only. Some reports may have incomplete information.
Do you take Dabigatran etexilate and have Gingival bleeding?Check whether Gingival bleeding is associated with a drug or a condition
How to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
Related publications that referenced our studies
- Fasullo, S., Davì, S., Cosenza, G., Di Franco, F., La Manna, N., Giubilato, A., ... & Maringhini, G. , "Acute agranulocytosis after oral administration of dabigatran: a rare case report and a short review of literature", Journal of thrombosis and thrombolysis, 2018 Jan .
How severe was Gingival bleeding and when was it recovered:
Expand to all the drugs that have ingredients of dabigatran etexilate:
Alternative drugs to, pros and cons of Dabigatran etexilate:
- Dabigatran etexilate (584 reports)
Gingival bleeding treatments and more:
- Gingival bleeding (13,996 reports)
COVID vaccines that are related to Gingival bleeding:
- Gingival bleeding in Moderna COVID Vaccine
- Gingival bleeding in Pfizer BioNTech Covid Vaccine
- Gingival bleeding in Johnson and Johnson Covid Vaccine
Common drugs associated with Gingival bleeding:
All the drugs that are associated with Gingival bleeding:
- Gingival bleeding (1,579 drugs)
Common conditions associated with Gingival bleeding:
All the conditions that are associated with Gingival bleeding:
- Gingival bleeding (976 conditions)
How the study uses the data?
The study uses data from the FDA. It is based on dabigatran etexilate (the active ingredients of Dabigatran etexilate) and Dabigatran etexilate (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Orencia and Ultram drug interaction - 14 seconds ago
- Paxil Cr and Night Sweats - 19 seconds ago
- Cefuroxime Axetil and Mepron drug interaction - 25 seconds ago
- Escitalopram and Chills - 34 seconds ago
- Pentamidine Isethionate and Radiation Necrosis - 40 seconds ago
- Extavia and Food Allergy - 48 seconds ago
- Capoten and Rheumatoid Arthritis - 56 seconds ago
- Nuvaring and Atherosclerosis - a minute ago
- Ondansetron and Chronic Myeloid Leukaemia - a minute ago
- Kayexalate and Baby Aspirin drug interaction - 2 minutes ago